IBio (IBIO +7.9%) says the NYSE Amex confirmed positive resolution of the biotech company's listing deficiency. In November, the exchange indicated its review of iBio's Form 10-K for the fiscal year ended June 20, 2011 showed the company was not in compliance with Section 1003(1)(iv). (submitted by M.E. Garza)